

# GLOBAL MARKETS FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS



PHM117A  
September 2012

Shalini Shahani Dewan  
*Project Analyst*

ISBN: 0-89336-104-6

**bcc** | Research  
Market Forecasting

**BCC Research**  
49 Walnut Park, Building 2  
Wellesley, MA 02481  
866-285-7215, 781-489-7301  
[www.bccresearch.com](http://www.bccresearch.com)  
Custom Reports: [carol.laverty@bccresearch.com](mailto:carol.laverty@bccresearch.com)

**TABLE OF CONTENTS**

<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 1 INTRODUCTION	1
STUDY OBJECTIVES	1
REASONS FOR DOING THIS STUDY	1
CONTRIBUTIONS OF THE STUDY AND FOR WHOM	1
SCOPE OF THE STUDY	2
METHODOLOGY	2
INFORMATION SOURCES	2
ABOUT THE AUTHOR	2
RELATED BCC RESEARCH REPORTS	3
BCC ONLINE SERVICES	3
DISCLAIMER	3
CHAPTER 2 EXECUTIVE SUMMARY	5
<i>SUMMARY TABLE GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, THROUGH 2017 (\$ MILLIONS)</i>	6
<i>SUMMARY FIGURE GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010-2017 (\$ MILLIONS)</i>	6
CHAPTER 3 OVERVIEW	8
THE BRAIN	8
CEREBRAL CORTEX	8
BRAIN STEM	9
SPINAL CORD	10
NEUROTRANSMITTERS	11
CLASSIFICATION OF NEURODEGENERATIVE DISORDERS	11
<i>TABLE 1 CLASSIFICATION OF SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY PRIMARY CLINICAL/PATHOLOGICAL FEATURE</i>	12
NEURODEGENERATIVE DISORDERS	12
ALZHEIMER'S DISEASE	12
LEWY BODY DEMENTIA	13
PICK'S DISEASE	13
HUNTINGTON'S DISEASE	13
CORTICAL BASAL GANGLIONIC DEGENERATION	14
PARKINSON'S DISEASE	14
MULTIPLE SYSTEM ATROPHY	14
PROGRESSIVE SUPRANUCLEAR PALSY	14
HALLERVORDEN-SPATZ DISEASE	15
DIAGNOSTIC TESTS FOR NEURODEGENERATIVE DISORDERS	15
DIAGNOSTIC TESTS FOR PARKINSON'S	15
DIAGNOSTIC TESTS FOR ALZHEIMER'S	16
DIAGNOSTIC TESTS FOR PICK'S DISEASE	16
DIAGNOSTIC TESTS FOR MULTIPLE SYSTEM ATROPHY	16
DIAGNOSTIC TESTS FOR PROGRESSIVE SUPRANUCLEAR PALSY	17
DIAGNOSTIC TESTS FOR CORTICAL BASAL GANGLIONIC DEGENERATION	17
DIAGNOSTIC TESTS FOR LEWY BODY DEMENTIA	17
DIAGNOSTIC TESTS FOR HALLERVORDEN-SPATZ DISEASE	17

<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 4 REGULATORY ASPECTS	19
INTRODUCTION	19
DRUG APPROVALS	19
<i>TABLE 2 ANDA AND NDA APPROVALS OF DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010 TO MARCH 2012</i>	20
<i>TABLE 3 PENDING NEW DRUG APPLICATIONS FOR DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS</i>	22
<i>TABLE 4 FDA DRUG SAFETY ALERTS, 2010 TO MARCH 2012</i>	22
<i>TABLE 5 FDA RECALLS OF DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010 TO MARCH 2012</i>	23
REGULATORY DEVELOPMENTS AFFECTING SYNDROMES OF DEMENTIA AND MOVEMENT DISORDER PRODUCTS	23
CHAPTER 5 NEW DEVELOPMENTS	25
<i>TABLE 6 NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2012</i>	25
<i>TABLE 7 NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2011</i>	30
<i>TABLE 8 NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010</i>	39
CHAPTER 6 GLOBAL MARKETS	45
MARKETS BY CLINICAL/PATHOLOGICAL FEATURE	45
MARKET OVERVIEW	45
MARKET REVENUES	46
<i>TABLE 9 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, THROUGH 2017 (\$ MILLIONS)</i>	46
<i>FIGURE 1 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010-2017 (\$ MILLIONS)</i>	47
MARKET SHARE	47
<i>TABLE 10 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT NEURODEGENERATIVE DISORDERS BY CLINICAL/PATHOLOGICAL FEATURE, 2011 (%)</i>	47
<i>FIGURE 2 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT NEURODEGENERATIVE DISORDERS BY CLINICAL/PATHOLOGICAL FEATURE, 2011 (%)</i>	47
MARKET BY DISEASE TYPE	48
MARKET OVERVIEW	49
MARKET REVENUES	50
<i>TABLE 11 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MAJOR NEURODEGENERATIVE DISORDERS, THROUGH 2017 (\$ MILLIONS)</i>	50
<i>FIGURE 3 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MAJOR NEURODEGENERATIVE DISORDERS, 2010-2017 (\$ MILLIONS)</i>	50
MARKET SHARE	51
<i>TABLE 12 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY DISEASE TYPE, 2011 (%)</i>	51
<i>FIGURE 4 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY DISEASE, 2011 (%)</i>	52
MARKET BY REGION	52
MARKET OVERVIEW	52
MARKET REVENUE	53

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 13 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	53
<i>FIGURE 5 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2010-2017 (\$ MILLIONS)</i>	53
MARKET SHARE	54
<i>TABLE 14 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2011 (%)</i>	54
<i>FIGURE 6 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2011 (%)</i>	54
MARKETS BY TECHNOLOGY	54
MARKET OVERVIEW	55
MARKET REVENUE	55
<i>TABLE 15 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, THROUGH 2017 (\$ MILLIONS)</i>	56
<i>FIGURE 7 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2010-2017 (\$ MILLIONS)</i>	56
MARKET SHARE	57
<i>TABLE 16 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2011 (%)</i>	57
<i>FIGURE 8 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2011 (%)</i>	57
CHAPTER 7 MARKET FOR DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA	59
MARKET BY DISEASE TYPE	60
ALZHEIMER'S DISEASE	60
LEWY BODY DEMENTIA	61
PICK'S DISEASE	61
MARKET OVERVIEW	62
MARKET REVENUE	63
<i>TABLE 17 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA, THROUGH 2017 (\$ MILLIONS)</i>	64
<i>FIGURE 9 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA, 2010-2017 (\$ MILLIONS)</i>	64
MARKET SHARE	64
<i>TABLE 18 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA BY DISEASE TYPE, 2011 (%)</i>	65
<i>FIGURE 10 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA BY DISEASE TYPE, 2011 (%)</i>	65
MARKET BY REGION	65
MARKET OVERVIEW	65
MARKET REVENUE	66
<i>TABLE 19 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	66
<i>FIGURE 11 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA BY REGION, 2010-2017 (\$ MILLIONS)</i>	66
MARKET SHARE	67
<i>TABLE 20 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA BY REGION, 2011 (%)</i>	67
<i>FIGURE 12 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA BY REGION, 2011 (%)</i>	67

<b>TOPIC</b>	<b>PAGE NO.</b>
REGIONAL MARKETS BY DISEASE TYPE	68
ALZHEIMER'S DISEASE	68
<i>TABLE 21 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT ALZHEIMER'S DISEASE BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	68
<i>FIGURE 13 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT ALZHEIMER'S DISEASE BY REGION, 2010-2017 (\$ MILLIONS)</i>	68
LEWY BODY DEMENTIA	69
<i>TABLE 22 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT LEWY BODY DEMENTIA BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	69
<i>FIGURE 14 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT LEWY BODY DEMENTIA BY REGION, 2010-2017 (\$ MILLIONS)</i>	70
PICK'S DISEASE	70
<i>TABLE 23 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PICK'S DISEASE BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	70
<i>FIGURE 15 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PICK'S DISEASE BY REGION, 2010-2017 (\$ MILLIONS)</i>	71
MARKET BY TECHNOLOGY	71
SMALL MOLECULES	72
MONOCLONAL ANTIBODIES	73
OTHERS	74
Immunization Strategy	74
Tau Tangling Inhibitors	75
Aminothienopyridazine (ATPZ) Analogues	75
Biomarkers	75
Stem Cells	76
MARKET OVERVIEW	76
MARKET REVENUE	77
<i>TABLE 24 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA BY TECHNOLOGY, THROUGH 2017 (\$ MILLIONS)</i>	77
<i>FIGURE 16 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA BY TECHNOLOGY, 2010-2017 (\$ MILLIONS)</i>	77
MARKET SHARE	78
<i>TABLE 25 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA BY TECHNOLOGY, 2011 (%)</i>	78
<i>FIGURE 17 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA BY TECHNOLOGY, 2011 (%)</i>	78
INDUSTRY STRUCTURE	79
LEADING MANUFACTURERS OF ALZHEIMER'S DRUGS	79
<i>TABLE 26 LEADING MANUFACTURERS/DISTRIBUTORS OF DRUGS/THERAPIES USED TO TREAT ALZHEIMER'S DISEASE</i>	80
MARKET SHARES OF LEADING MANUFACTURERS OF ALZHEIMER'S DRUGS	82
<i>TABLE 27 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT ALZHEIMER'S DISEASE, 2011 (%)</i>	82
<i>FIGURE 18 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT ALZHEIMER'S DISEASE, 2011 (%)</i>	82
LEADING MANUFACTURERS OF DRUGS USED TO TREAT LEWY BODY DEMENTIA	83
<i>TABLE 28 LEADING MANUFACTURERS/DISTRIBUTORS OF DRUGS/THERAPIES USED TO TREAT LEWY BODY DEMENTIA</i>	84
MARKET SHARES OF LEADING MANUFACTURERS OF DRUGS USED TO TREAT LEWY BODY DEMENTIA	85

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 29 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT LEWY BODY DEMENTIA, 2011 (%)</i>	85
<i>FIGURE 19 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT LEWY BODY DEMENTIA, 2011 (%)</i>	86
LEADING MANUFACTURERS OF DRUGS USED TO TREAT PICK'S DISEASE	87
<i>TABLE 30 LEADING MANUFACTURERS/ DISTRIBUTORS OF DRUGS/THERAPIES USED TO TREAT PICK'S DISEASE</i>	87
MARKET SHARES OF LEADING MANUFACTURERS OF DRUGS USED TO TREAT PICK'S DISEASE	89
<i>TABLE 31 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PICK'S DISEASE, 2011 (%)</i>	89
<i>FIGURE 20 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PICK'S DISEASE, 2011 (%)</i>	89
CHAPTER 8 MARKET FOR DRUGS TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES	92
MARKET BY DISEASE TYPE	92
HUNTINGTON'S DISEASE	92
CORTICOBASAL GANGLIONIC DEGENERATION	93
MARKET OVERVIEW	93
<i>TABLE 32 CHDI FOUNDATIONS' KEY DEVELOPMENTS IN TREATING HUNTINGTON'S DISEASE</i>	94
MARKET REVENUE	95
<i>TABLE 33 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TYPE OF DISEASE, THROUGH 2017 (\$ MILLIONS)</i>	95
<i>FIGURE 21 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TYPE OF DISEASE, 2010-2017 (\$ MILLIONS)</i>	95
MARKET SHARE	96
<i>TABLE 34 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY DISEASE TYPE, 2011 (%)</i>	96
<i>FIGURE 22 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY DISEASE TYPE, 2011 (%)</i>	96
MARKET BY REGION	97
MARKET OVERVIEW	97
<i>TABLE 35 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	98
<i>FIGURE 23 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, 2010-2017 (\$ MILLIONS)</i>	98
MARKET SHARE	99
<i>TABLE 36 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, 2011 (%)</i>	99
<i>FIGURE 24 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, 2011 (%)</i>	99
REGIONAL MARKETS BY DISEASE TYPE	99
HUNTINGTON'S DISEASE	99
<i>TABLE 37 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT HUNTINGTON'S DISEASE BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	100
<i>FIGURE 25 GLOBAL SALES OF DRUGS USED TO TREAT HUNTINGTON'S DISEASE BY REGION, 2010-2017 (\$ MILLIONS)</i>	100

<b>TOPIC</b>	<b>PAGE NO.</b>
CORTICOBASAL GANGLIONIC DEGENERATION	100
<i>TABLE 38 GLOBAL SALES OF DRUGS USED TO TREAT CORTICOBASAL GANGLIONIC DEGENERATION BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	101
<i>FIGURE 26 GLOBAL SALES OF DRUGS USED TO TREAT CORTICOBASAL GANGLIONIC DEGENERATION BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	101
MARKET BY TECHNOLOGY	101
SMALL MOLECULES	102
MONOCLONAL ANTIBODIES	103
OTHERS	104
Stem Cells	104
Biomarkers	105
MARKET OVERVIEW	105
MARKET REVENUE	106
<i>TABLE 39 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, THROUGH 2017 (\$ MILLIONS)</i>	107
<i>FIGURE 27 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, 2010-2017 (\$ MILLIONS)</i>	107
MARKET SHARE	107
<i>TABLE 40 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, 2011 (%)</i>	108
<i>FIGURE 28 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, 2011 (%)</i>	108
INDUSTRY STRUCTURE	108
LEADING MANUFACTURERS OF DRUGS USED TO TREAT HUNTINGTON'S DISEASE	108
<i>TABLE 41 LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TO TREAT HUNTINGTON'S DISEASE</i>	109
MARKET SHARES OF LEADING MANUFACTURERS OF DRUGS USED TO TREAT HUNTINGTON'S DISEASE	111
<i>TABLE 42 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT HUNTINGTON'S DISEASE, 2011 (%)</i>	111
<i>FIGURE 29 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS FOR USED TO TREAT HUNTINGTON'S DISEASE, 2011 (%)</i>	112
LEADING MANUFACTURERS OF DRUGS USED TO TREAT CORTICOBASAL GANGLIONIC DEGENERATION	113
<i>TABLE 43 LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TO TREAT HUNTINGTON'S DISEASE</i>	113
MARKET SHARES OF LEADING MANUFACTURERS OF DRUGS USED TO TREAT CORTICOBASAL GANGLIONIC DEGENERATION	114
<i>TABLE 44 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT CORTICOBASAL GANGLIONIC DEGENERATION, 2011 (%)</i>	114
<i>FIGURE 30 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUGS USED TO TREAT CORTICOBASAL GANGLIONIC DEGENERATION, 2011 (%)</i>	115
CHAPTER 9 MARKET FOR MOVEMENT DISORDER SYNDROMES	117
MARKET BY TYPE OF DISEASE	117
PARKINSON'S DISEASE	117
MULTIPLE SYSTEM ATROPHY	118
PROGRESSIVE SUPRANUCLEAR PALSY	119
HALLERVORDEN-SPATZ DISEASE	119

<b>TOPIC</b>	<b>PAGE NO.</b>
MARKET OVERVIEW	120
<i>TABLE 45 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY DISEASE TYPE, THROUGH 2017 (\$ MILLIONS)</i>	122
<i>FIGURE 31 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY DISEASE TYPE, 2010-2017 (\$ MILLIONS)</i>	122
MARKET SHARE	123
<i>TABLE 46 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY DISEASE TYPE, 2011 (%)</i>	123
<i>FIGURE 32 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY DISEASE TYPE, 2011 (%)</i>	124
MARKETS BY REGION	124
MARKET OVERVIEW	124
MARKET REVENUE	125
<i>TABLE 47 GLOBAL SALES OF DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	125
<i>FIGURE 33 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY REGION, 2010-2017 (\$ MILLIONS)</i>	126
MARKET SHARE	126
<i>TABLE 48 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY REGION, 2011 (%)</i>	126
<i>FIGURE 34 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY REGION, 2011 (%)</i>	126
REGIONAL MARKETS BY DISEASE TYPE	127
PARKINSON'S DISEASE	127
<i>TABLE 49 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PARKINSON'S DISEASE BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	128
<i>FIGURE 35 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PARKINSON'S DISEASE BY REGION, 2010-2017 (\$ MILLIONS)</i>	128
MULTIPLE SYSTEM ATROPHY	128
<i>TABLE 50 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MULTIPLE SYSTEM ATROPHY BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	129
<i>FIGURE 36 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MULTIPLE SYSTEM ATROPHY BY REGION, 2010-2017 (\$ MILLIONS)</i>	129
PROGRESSIVE SUPRANUCLEAR PALSY	129
<i>TABLE 51 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE SUPRANUCLEAR PALSY BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	130
<i>FIGURE 37 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE SUPRANUCLEAR PALSY BY REGION, 2010-2017 (\$ MILLIONS)</i>	130
HALLERVORDEN-SPATZ DISEASE	131
<i>TABLE 52 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT HALLERVORDEN-SPATZ DISEASE BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	131
<i>FIGURE 38 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT HALLERVORDEN-SPATZ DISEASE BY REGION, 2010-2017 (\$ MILLIONS)</i>	131
MARKET BY TECHNOLOGY	132
SMALL MOLECULES	132
MONOCLONAL ANTIBODIES	133
OTHERS	133
Tau Tangling Inhibitors	133
Biomarkers	133
Stem Cells	134



TOPIC	PAGE NO.
MARKET OVERVIEW	135
MARKET REVENUE	136
<i>TABLE 53 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY TECHNOLOGY, THROUGH 2017 (\$ MILLIONS)</i>	136
<i>FIGURE 39 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY TECHNOLOGY, 2010-2017 (\$ MILLIONS)</i>	137
MARKET SHARE	137
<i>TABLE 54 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY TECHNOLOGY, 2011 (%)</i>	137
<i>FIGURE 40 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY TECHNOLOGY, 2011 (%)</i>	137
INDUSTRY STRUCTURE	138
LEADING MANUFACTURERS OF DRUGS USED TO TREAT PARKINSON'S DISEASE	138
<i>TABLE 55 LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TO TREAT PARKINSON'S DISEASE</i>	138
MARKET SHARES OF LEADING MANUFACTURERS OF DRUGS USED TO TREAT PARKINSON'S DISEASE	141
<i>TABLE 56 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PARKINSON'S DISEASE, 2011 (%)</i>	141
<i>FIGURE 41 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PARKINSON'S DISEASE, 2011 (%)</i>	142
LEADING MANUFACTURERS OF DRUGS USED TO TREAT MULTIPLE SYSTEM ATROPHY	143
<i>TABLE 57 LEADING MANUFACTURERS/DISTRIBUTORS OF DRUGS/THERAPIES USED TO TREAT MULTIPLE SYSTEM ATROPHY</i>	143
MARKET SHARES OF LEADING MANUFACTURERS OF DRUGS USED TO TREAT MULTIPLE SYSTEM ATROPHY	144
<i>TABLE 58 MANUFACTURERS/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MULTIPLE SYSTEM ATROPHY, 2011 (%)</i>	144
<i>FIGURE 42 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MULTIPLE SYSTEM ATROPHY, 2011 (%)</i>	144
LEADING MANUFACTURERS OF DRUGS USED TO TREAT PROGRESSIVE SUPRANUCLEAR PALSY	145
<i>TABLE 59 LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TO TREAT PROGRESSIVE SUPRANUCLEAR PALSY</i>	145
MARKET SHARES OF LEADING MANUFACTURERS OF DRUGS USED TO TREAT PROGRESSIVE SUPRANUCLEAR PALSY	147
<i>TABLE 60 MANUFACTURERS/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE SUPRANUCLEAR PALSY, 2011 (%)</i>	147
<i>FIGURE 43 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE SUPRANUCLEAR PALSY, 2011 (%)</i>	148
LEADING MANUFACTURERS OF DRUGS USED TO TREAT HALLERVORDEN-SPATZ DISEASE	149
<i>TABLE 61 LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TO TREAT HALLERVORDEN-SPATZ DISEASE</i>	149
MARKET SHARES OF LEADING MANUFACTURERS OF DRUGS USED TO TREAT HALLERVORDEN-SPATZ DISEASE	150
<i>TABLE 62 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT HALLERVORDEN-SPATZ DISEASE, 2011 (%)</i>	150
<i>FIGURE 44 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT HALLERVORDEN-SPATZ DISEASE, 2011 (%)</i>	151

<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 10 PATENT ANALYSIS	153
PATENTS ISSUED BY YEAR	153
TABLE 63 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS ISSUED PER YEAR, 2010-MARCH 2012 (NO.)	154
FIGURE 45 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS ISSUED PER YEAR, 2010—MARCH 2012 (NO.)	154
FIGURE 46 PERCENTAGE OF U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS ISSUED PER YEAR, 2010-MARCH 2012 (%)	155
PATENTS BY DISEASE CATEGORY	155
TABLE 64 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY CATEGORY OF DISEASE, 2010-MARCH 2012 (NO.)	155
FIGURE 47 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY CATEGORY OF DISEASE, 2010-MARCH 2012 (NO.)	156
PATENTS BY DISEASE TYPE	156
SYNDROMES OF DEMENTIA	156
TABLE 65 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA (PROGRESSIVE DEMENTIA) BY CLINICAL/PATHOLOGICAL FEATURE, 2010-MARCH 2012 (NO.)	157
FIGURE 48 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA BY CLINICAL/PATHOLOGICAL FEATURE, 2010-MARCH 2012* (NO.)	157
MOVEMENT DISORDER SYNDROMES	157
TABLE 66 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY DISEASE TYPE, 2010-MARCH 2012 (NO.)	158
FIGURE 49 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY DISEASE TYPE, 2010-MARCH 2012 (NO.)	158
PATENTS BY COUNTRY	158
SYNDROMES OF DEMENTIA (PROGRESSIVE DEMENTIA)	158
TABLE 67 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA (PROGRESSIVE DEMENTIA) BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (NO.)	159
FIGURE 50 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA (PROGRESSIVE DEMENTIA) BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (NO.)	160
TABLE 68 U.S. PATENT SHARES OF DRUGS USED TO TREAT PROGRESSIVE DEMENTIA BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (%)	160
MOVEMENT DISORDER SYNDROMES	161
TABLE 69 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (NO.)	162
FIGURE 51 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (NO.)	162
TABLE 70 U.S. PATENT SHARES OF DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (%)	163
PATENTS BY COMPANY	164
SYNDROMES OF DEMENTIA (PROGRESSIVE DEMENTIA)	164
TABLE 71 NUMBER OF U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA (PROGRESSIVE DEMENTIA) BY COMPANY, 2010-MARCH 2012 (NO.)	165
MOVEMENT DISORDER SYNDROMES	169
TABLE 72 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY COMPANY, 2010-MARCH 2012 (NO.)	170
CHAPTER 11 CURRENT SITUATION	174
MARKET TRENDS	174
SYNDROMES OF DEMENTIA	174

<b>TOPIC</b>	<b>PAGE NO.</b>
Market Drivers	175
MOVEMENT DISORDER SYNDROMES	176
Market Drivers	177
OVERALL DRIVERS OF THE MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS	177
OTHER FACTORS AFFECTING THE MARKET	178
COLLABORATIONS/MERGERS AND ACQUISITIONS	178
CHAPTER 12 COMPANY PROFILES	182
ABBOTT LABORATORIES	182
ABLYNX NV	183
ACCERA INC.	183
ACORDA THERAPEUTICS INC.	184
ACTAVIS ELIZABETH	184
AFFIRIS AG	185
ALLIANCE PHARMA PLC	185
ALLON THERAPEUTICS INC.	186
ALPHAPHARM	186
ALZHYME LTD.	187
AMERICAN REGENT INC.	187
APOTEX INC.	188
APOTHECA INC.	188
ASTELLAS PHARMA INC.	188
ASTRAZENECA GMBH	189
AUROBINDO PHARMA LTD.	190
BAXTER INTERNATIONAL INC.	190
BELLUS HEALTH INC.	191
BOEHRINGER INGELHEIM LTD.	191
BRISTOL-MYERS SQUIBB	192
BRYANT RANCH PREPACK	193
CADILA HEALTHCARE LTD.	193
CARACO PHARMACEUTICAL LABORATORIES	194
CARDINAL HEALTH	194
CELLZOME AG	195
CIPLA LTD.	195
COGNITION THERAPEUTICS INC.	196
COLUCID PHARMACEUTICALS INC.	196
COMENTIS INC.	196
CORTEX PHARMACEUTICALS	197
CYTOS BIOTECHNOLOGY AG	197
DAIICHI SANKYO CO. LTD.	198
DR. REDDY'S LABORATORIES LTD.	198
EISAI CO. LTD.	199
ELAN PHARMA INTERNATIONAL LTD.	200
ELI LILLY AND CO.	200
ENDO PHARMACEUTICALS INC.	201
ENVIVO PHARMACEUTICALS	201
EVOTEC AG	202

TOPIC	PAGE NO.
EPITOMICS INC.	203
EXONHIT THERAPEUTICS SA	203
FOREST LABORATORIES INC.	203
GLAXOSMITHKLINE PLC	204
GLENMARK GENERICS LTD.	205
H. LUNDBECK A/S	206
HAMELN PHARMACEUTICALS LTD.	207
HELICON THERAPEUTICS INC.	207
HOSPIRA INC.	207
INTELLECT NEUROSCIENCES INC.	208
INTRA-CELLULAR THERAPIES INC.	208
JAZZ PHARMACEUTICALS PLC	209
MAJOR PHARMACEUTICALS	209
MEDIVATION INC.	210
MEMORY PHARMACEUTICALS CORP.	210
MERCK SERONO	210
MERCK SHARP & DOHME LTD.	211
MERZ PHARMA GMBH & CO KGAA	211
MITHRIDION INC.	212
MYLAN PHARMACEUTICALS	212
NEUREN PHARMACEUTICALS LTD.	213
NEURO-HITECH INC.	214
NEUROPTIX CORP.	214
NEUROSEARCH A/S	215
NEWRON PHARMACEUTICALS SPA	216
NOSCIRA SA	216
NOVARTIS AG	217
NYMOX PHARMACEUTICAL CORP.	217
ORCHID CHEMICALS & PHARMACEUTICALS LTD.	218
ORION CORP.	218
ORTHO-MCNEIL JANSSEN PHARMACEUTICALS INC.	219
PAR PHARMACEUTICALS	219
PERRIGO CO.	220
PFIZER INC.	220
PHARNEXT	221
PHYSICIANS TOTAL CARE INC.	222
PLIVA HRVATSKA D.O.O.	222
PRASCO LABORATORIES	223
RANBAXY LABORATORIES LTD.	223
ROCHE HOLDING LTD.	224
ROXANE LABORATORIES INC.	224
SANDOZ INTERNATIONAL GMBH	225
SANOFI	225
SANTHERA PHARMACEUTICALS	226
SHIONOGI & CO.	227
STADA ARZNEIMITTEL AG	227
SUN PHARMA	228

<b>TOPIC</b>	<b>PAGE NO.</b>
TAJ PHARMACEUTICALS LTD.	229
TAKEDA PHARMACEUTICAL CO. LTD.	229
TERCICA INC.	230
TEVA PHARMACEUTICAL INDUSTRIES LTD.	230
TORRENT PHARMA	231
UCB SA	232
UDL LABORATORIES	232
UPSHER-SMITH LABORATORIES	233
VALEANT PHARMACEUTICALS	233
VERNALIS PLC	234
WATSON PHARMACEUTICALS INC.	234
WEST-WARD PHARMACEUTICAL	235
CHAPTER 13 APPENDIX I: ABBREVIATIONS	238

**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, THROUGH 2017 (\$ MILLIONS)	6
TABLE 1 CLASSIFICATION OF SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY PRIMARY CLINICAL/PATHOLOGICAL FEATURE	12
TABLE 2 ANDA AND NDA APPROVALS OF DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010 TO MARCH 2012	20
TABLE 3 PENDING NEW DRUG APPLICATIONS FOR DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS	22
TABLE 4 FDA DRUG SAFETY ALERTS, 2010 TO MARCH 2012	22
TABLE 5 FDA RECALLS OF DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010 TO MARCH 2012	23
TABLE 6 NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2012	25
TABLE 7 NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2011	30
TABLE 8 NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010	39
TABLE 9 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, THROUGH 2017 (\$ MILLIONS)	46
TABLE 10 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT NEURODEGENERATIVE DISORDERS BY CLINICAL/PATHOLOGICAL FEATURE, 2011 (%)	47
TABLE 11 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MAJOR NEURODEGENERATIVE DISORDERS, THROUGH 2017 (\$ MILLIONS)	50
TABLE 12 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY DISEASE TYPE, 2011 (%)	51
TABLE 13 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY REGION, THROUGH 2017 (\$ MILLIONS)	53
TABLE 14 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2011 (%)	54
TABLE 15 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, THROUGH 2017 (\$ MILLIONS)	56
TABLE 16 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2011 (%)	57
TABLE 17 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA, THROUGH 2017 (\$ MILLIONS)	64
TABLE 18 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA BY DISEASE TYPE, 2011 (%)	65
TABLE 19 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA BY REGION, THROUGH 2017 (\$ MILLIONS)	66
TABLE 20 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA BY REGION, 2011 (%)	67
TABLE 21 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT ALZHEIMER'S DISEASE BY REGION, THROUGH 2017 (\$ MILLIONS)	68
TABLE 22 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT LEWY BODY DEMENTIA BY REGION, THROUGH 2017 (\$ MILLIONS)	69
TABLE 23 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PICK'S DISEASE BY REGION, THROUGH 2017 (\$ MILLIONS)	70
TABLE 24 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA BY TECHNOLOGY, THROUGH 2017 (\$ MILLIONS)	77
TABLE 25 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA BY TECHNOLOGY, 2011 (%)	78

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 26 LEADING MANUFACTURERS/DISTRIBUTORS OF DRUGS/THERAPIES USED TO TREAT ALZHEIMER'S DISEASE	80
TABLE 27 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT ALZHEIMER'S DISEASE, 2011 (%)	82
TABLE 28 LEADING MANUFACTURERS/DISTRIBUTORS OF DRUGS/THERAPIES USED TO TREAT LEWY BODY DEMENTIA	84
TABLE 29 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT LEWY BODY DEMENTIA, 2011 (%)	85
TABLE 30 LEADING MANUFACTURERS/ DISTRIBUTORS OF DRUGS/THERAPIES USED TO TREAT PICK'S DISEASE	87
TABLE 31 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PICK'S DISEASE, 2011 (%)	89
TABLE 32 CHDI FOUNDATIONS' KEY DEVELOPMENTS IN TREATING HUNTINGTON'S DISEASE	94
TABLE 33 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TYPE OF DISEASE, THROUGH 2017 (\$ MILLIONS)	95
TABLE 34 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY DISEASE TYPE, 2011 (%)	96
TABLE 35 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, THROUGH 2017 (\$ MILLIONS)	98
TABLE 36 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, 2011 (%)	99
TABLE 37 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT HUNTINGTON'S DISEASE BY REGION, THROUGH 2017 (\$ MILLIONS)	100
TABLE 38 GLOBAL SALES OF DRUGS USED TO TREAT CORTICOBASAL GANGLIONIC DEGENERATION BY REGION, THROUGH 2017 (\$ MILLIONS)	101
TABLE 39 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, THROUGH 2017 (\$ MILLIONS)	107
TABLE 40 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, 2011 (%)	108
TABLE 41 LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TO TREAT HUNTINGTON'S DISEASE	109
TABLE 42 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT HUNTINGTON'S DISEASE, 2011 (%)	111
TABLE 43 LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TO TREAT HUNTINGTON'S DISEASE	113
TABLE 44 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT CORTICOBASAL GANGLIONIC DEGENERATION, 2011 (%)	114
TABLE 45 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY DISEASE TYPE, THROUGH 2017 (\$ MILLIONS)	122
TABLE 46 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY DISEASE TYPE, 2011 (%)	123
TABLE 47 GLOBAL SALES OF DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY REGION, THROUGH 2017 (\$ MILLIONS)	125
TABLE 48 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY REGION, 2011 (%)	126
TABLE 49 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PARKINSON'S DISEASE BY REGION, THROUGH 2017 (\$ MILLIONS)	128
TABLE 50 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MULTIPLE SYSTEM ATROPHY BY REGION, THROUGH 2017 (\$ MILLIONS)	129

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 51 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE SUPRANUCLEAR PALSY BY REGION, THROUGH 2017 (\$ MILLIONS)	130
TABLE 52 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT HALLERVORDEN-SPATZ DISEASE BY REGION, THROUGH 2017 (\$ MILLIONS)	131
TABLE 53 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY TECHNOLOGY, THROUGH 2017 (\$ MILLIONS)	136
TABLE 54 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY TECHNOLOGY, 2011 (%)	137
TABLE 55 LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TO TREAT PARKINSON'S DISEASE	138
TABLE 56 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PARKINSON'S DISEASE, 2011 (%)	141
TABLE 57 LEADING MANUFACTURERS/DISTRIBUTORS OF DRUGS/THERAPIES USED TO TREAT MULTIPLE SYSTEM ATROPHY	143
TABLE 58 MANUFACTURERS/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MULTIPLE SYSTEM ATROPHY, 2011 (%)	144
TABLE 59 LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TO TREAT PROGRESSIVE SUPRANUCLEAR PALSY	145
TABLE 60 MANUFACTURERS/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE SUPRANUCLEAR PALSY, 2011 (%)	147
TABLE 61 LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TO TREAT HALLERVORDEN-SPATZ DISEASE	149
TABLE 62 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT HALLERVORDEN-SPATZ DISEASE, 2011 (%)	150
TABLE 63 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS ISSUED PER YEAR, 2010-MARCH 2012 (NO.)	154
TABLE 64 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY CATEGORY OF DISEASE, 2010-MARCH 2012 (NO.)	155
TABLE 65 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA (PROGRESSIVE DEMENTIA) BY CLINICAL/PATHOLOGICAL FEATURE, 2010-MARCH 2012 (NO.)	157
TABLE 66 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY DISEASE TYPE, 2010-MARCH 2012 (NO.)	158
TABLE 67 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA (PROGRESSIVE DEMENTIA) BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (NO.)	159
TABLE 68 U.S. PATENT SHARES OF DRUGS USED TO TREAT PROGRESSIVE DEMENTIA BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (%)	160
TABLE 69 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (NO.)	162
TABLE 70 U.S. PATENT SHARES OF DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (%)	163
TABLE 71 NUMBER OF U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA (PROGRESSIVE DEMENTIA) BY COMPANY, 2010-MARCH 2012 (NO.)	165
TABLE 72 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY COMPANY, 2010-MARCH 2012 (NO.)	170



## LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010-2017 (\$ MILLIONS)	6
FIGURE 1 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010-2017 (\$ MILLIONS)	47
FIGURE 2 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT NEURODEGENERATIVE DISORDERS BY CLINICAL/PATHOLOGICAL FEATURE, 2011 (%)	47
FIGURE 3 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MAJOR NEURODEGENERATIVE DISORDERS, 2010-2017 (\$ MILLIONS)	50
FIGURE 4 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY DISEASE, 2011 (%)	52
FIGURE 5 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2010-2017 (\$ MILLIONS)	53
FIGURE 6 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2011 (%)	54
FIGURE 7 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2010-2017 (\$ MILLIONS)	56
FIGURE 8 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2011 (%)	57
FIGURE 9 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA, 2010-2017 (\$ MILLIONS)	64
FIGURE 10 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA BY DISEASE TYPE, 2011 (%)	65
FIGURE 11 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA BY REGION, 2010-2017 (\$ MILLIONS)	66
FIGURE 12 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA BY REGION, 2011 (%)	67
FIGURE 13 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT ALZHEIMER'S DISEASE BY REGION, 2010-2017 (\$ MILLIONS)	68
FIGURE 14 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT LEWY BODY DEMENTIA BY REGION, 2010-2017 (\$ MILLIONS)	70
FIGURE 15 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PICK'S DISEASE BY REGION, 2010-2017 (\$ MILLIONS)	71
FIGURE 16 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA BY TECHNOLOGY, 2010-2017 (\$ MILLIONS)	77
FIGURE 17 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA BY TECHNOLOGY, 2011 (%)	78
FIGURE 18 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT ALZHEIMER'S DISEASE, 2011 (%)	82
FIGURE 19 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT LEWY BODY DEMENTIA, 2011 (%)	86
FIGURE 20 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PICK'S DISEASE, 2011 (%)	89
FIGURE 21 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TYPE OF DISEASE, 2010-2017 (\$ MILLIONS)	95
FIGURE 22 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY DISEASE TYPE, 2011 (%)	96
FIGURE 23 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, 2010-2017 (\$ MILLIONS)	98
FIGURE 24 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, 2011 (%)	99

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
FIGURE 25 GLOBAL SALES OF DRUGS USED TO TREAT HUNTINGTON'S DISEASE BY REGION, 2010-2017 (\$ MILLIONS)	100
FIGURE 26 GLOBAL SALES OF DRUGS USED TO TREAT CORTICOBASAL GANGLIONIC DEGENERATION BY REGION, THROUGH 2017 (\$ MILLIONS)	101
FIGURE 27 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, 2010-2017 (\$ MILLIONS)	107
FIGURE 28 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, 2011 (%)	108
FIGURE 29 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS FOR USED TO TREAT HUNTINGTON'S DISEASE, 2011 (%)	112
FIGURE 30 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUGS USED TO TREAT CORTICOBASAL GANGLIONIC DEGENERATION, 2011 (%)	115
FIGURE 31 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY DISEASE TYPE, 2010-2017 (\$ MILLIONS)	122
FIGURE 32 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY DISEASE TYPE, 2011 (%)	124
FIGURE 33 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY REGION, 2010-2017 (\$ MILLIONS)	126
FIGURE 34 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY REGION, 2011 (%)	126
FIGURE 35 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PARKINSON'S DISEASE BY REGION, 2010-2017 (\$ MILLIONS)	128
FIGURE 36 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MULTIPLE SYSTEM ATROPHY BY REGION, 2010-2017 (\$ MILLIONS)	129
FIGURE 37 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE SUPRANUCLEAR PALSY BY REGION, 2010-2017 (\$ MILLIONS)	130
FIGURE 38 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT HALLERVORDEN-SPATZ DISEASE BY REGION, 2010-2017 (\$ MILLIONS)	131
FIGURE 39 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY TECHNOLOGY, 2010-2017 (\$ MILLIONS)	137
FIGURE 40 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY TECHNOLOGY, 2011 (%)	137
FIGURE 41 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PARKINSON'S DISEASE, 2011 (%)	142
FIGURE 42 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MULTIPLE SYSTEM ATROPHY, 2011 (%)	144
FIGURE 43 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE SUPRANUCLEAR PALSY, 2011 (%)	148
FIGURE 44 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT HALLERVORDEN-SPATZ DISEASE, 2011 (%)	151
FIGURE 45 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS ISSUED PER YEAR, 2010—MARCH 2012 (NO.)	154
FIGURE 46 PERCENTAGE OF U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS ISSUED PER YEAR, 2010-MARCH 2012 (%)	155
FIGURE 47 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY CATEGORY OF DISEASE, 2010-MARCH 2012 (NO.)	156
FIGURE 48 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA BY CLINICAL/PATHOLOGICAL FEATURE, 2010-MARCH 2012* (NO.)	157
FIGURE 49 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY DISEASE TYPE, 2010-MARCH 2012 (NO.)	158
FIGURE 50 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA (PROGRESSIVE DEMENTIA) BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (NO.)	160

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
FIGURE 51 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (NO.)	162